Dronedarone provides effective early rhythm control : post-hoc analysis of the ATHENA trial using EAST-AFNET 4 criteria
Aims This post-hoc analysis of the ATHENA trial assessed whether dronedarone (400 mg twice daily) improved cardiovascular outcomes compared with placebo in patients with early atrial fibrillation/atrial flutter (AF) and cardiovascular comorbidities, based on EAST-AFNET 4 inclusion criteria and outcomesMethods The co-primary outcomes were (i) a composite of cardiovascular death, stroke, or hospital